Five-year study by OHSU Cancer Institute shows Gleevec's excellent survival rate

December 06, 2006

PORTLAND, Ore. -- In five years Gleevec, the little yellow pill, has proved itself to be a miracle drug for most patients who take it.

When the drug first was developed by Brian J. Druker, M.D., the leukemia program leader of the Oregon Health & Science University Cancer Institute, the overall survival rate for patients with chronic myelogenous leukemia (CML) taking this new experimental drug was unknown.

"We've completely changed the outlook for patients with this disease. Before Gleevec, patients were fortunate if they lived five years. Now, we've given patients a hopeful future," said Druker, the principal investigator for the study.

Today, after five years, the overall survival of 553 subjects randomized to receive Gleevec as their initial therapy is nearly 90 percent, 95 percent if only deaths related to CML are considered. Just 5 percent of subjects discontinued Gleevec because of side effects. The results are published in the Dec. 7 issue of the New England Journal of Medicine.

This study also shows that the risk of relapse has trended downward during the past three years. In the study's fifth year, less than 1 percent of patients progressed from the chronic phase to more advanced phases of the disease.

"This trend, coupled with the low risk of relapse, means that the possibility of long-term survival with CML is increasingly likely," Druker said.

The five-year study was conducted at 117 centers in 16 countries.

Gleevec also has a larger story to tell. Its targeted therapy approach broke new ground in how to treat cancer. By specifically targeting the cancerous cells, the healthy cells are left unharmed. Gleevec is changing cancer research and the drug is a harbinger of new agents for curing or controlling all cancers. "We are at an important juncture," Druker said, "not unlike the early 1900s where scientists turned infectious diseases from routinely fatal into manageable, curable or preventable diseases. We are on the cusp of turning cancer into a manageable disease."

Gleevec is a signal transduction inhibitor that interferes with the enzymes that trigger the growth of cancerous cells. Gleevec acts on CML cells by inhibiting the disease-causing enzyme BCR-ABL that tells cells to grow and divide.

Gleevec has also been approved for people with advanced gastrointestinal stromal tumors, dermatofibrosarcoma protuberans, Philadelphia chromosome-positive acute lymphoblastic leukemia, certain forms of myeloproliferative disorders, hypereosinophilic syndrome, and aggressive systemic mastocytosis.

Gleevec was co-developed and marketed by the pharmaceutical company Novartis.

Brian Druker, M.D., is the JELD-WEN Chair of Leukemia Research at the Oregon Health & Science University Cancer Institute and an Investigator of the Howard Hughes Medical Institute.
The OHSU Cancer Institute is the only cancer center designated by the National Cancer Institute between Sacramento and Seattle. It comprises some 120 clinical researchers, basic scientists and population scientists who work together to translate scientific discoveries into longer and better lives for Oregon's cancer patients. In the lab, basic scientists examine cancer cells and normal cells to uncover molecular abnormalities that cause the disease. This basic science informs more than 200 clinical trials conducted at the OHSU Cancer Institute.

Oregon Health & Science University

Related Side Effects Articles from Brightsurf:

Side effects often attributed to statins were the same for those taking a placebo
Study participants who reported side effects from cholesterol-lowering medications known as statins also reported the same side effects when they unknowingly took placebo pills.

Cancer treatment without side effects?
Treating cancer without debilitating side effects has long been the holy grail of oncologists, and researchers at the University of California, Irvine and Switzerland's Lausanne University Hospital may have found it.

Finding cortisone alternatives with fewer side effects
Many people use cortisone of a regular basis. It is used for treating rheumatism, asthma, multiple sclerosis, or even COVID-19.

Blood-thinner with no bleeding side-effects is here
In a study led by EPFL, scientists have developed a synthetic blood-thinner that, unlike all others, doesn't cause bleeding side-effects.

Predicting side effects
Scientists develop AI-based tool to predict adverse drug events. Such events are responsible for some 2 million U.S. hospitalizations per year.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

What if we could design powerful drugs without unwanted side effects?
The paper describes how to minimize or eliminate side effects in drugs that target G protein-coupled receptors.

Variation in how side effects are reported clouds drug safety
University of Colorado Cancer Center study finds significant variation in how drug side effects are reported, potentially making some drugs seem safer or less safe than they really are.

New drug can ease the side effects of medication against severe depression
Today, severe depressions require a high dose of antidepressants. However, the high dose may also cause serious side effects.

University of Cincinnati research looks at side effects for pediatric medications
Dr. Jeffrey Strawn, associate professor in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati College of Medicine, and Jeffrey Mills, associate professor in the Department of Economics at the UC Lindner College of Business, published a study in the Journal of the American Academy of Child & Adolescent Psychiatry looking specifically at side effects that impact children and adolescents being treated for anxiety disorders and obsessive-compulsive disorder (OCD).

Read More: Side Effects News and Side Effects Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to